Shanghai, China, October 11, 2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company") today announced the dosing of the first cohort was successfully completed for SIMR’s SR1375 in the first-in-human study on October 8.
SR1375 is an asset of first-in-class potential for a range of diseases including diabetic retinopathy (DR). The primary objectives of first-in-human study are to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of SR1375 in healthy subjects.
Dr. Kai Wu, Co-CEO and Head of Clinical Development of SIMR, said: “SR1375 is the second candidate drug of SIMR entering the clinic phase. We are very excited about the successful completion of the first cohort dosing, which is an important milestone for SR1375 and represents the expansion of company pipeline and its relevant disease areas.”
SR1375 is a small molecular of neuroinflammatory mechanisms, implicated in several diseases including DR. Anti-vascular endothelial growth factor (Anti-VEGF) is the established first-line treatment for visual impairment in DR. However, about 50% of DR patients showed partial or no response to Anti-VEGF treatment. The advantages of SR1375 include unique mechanism of action and convenience of oral administration, as well as comparable efficacy to Anti-VEGF in animal models. It has the potential to provide a more convenient, safe and effective option for DR patients.
SIMR is a biotechnology company dedicated to the discovery and development of innovative drugs for pain, inflammation and central nervous system related diseases. Since its establishment in 2014, the company has established a research and development platform of more than 3,000 square meters, with comprehensive drug discovery and development capabilities.